X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
drug combinations (1159) 1159
humans (1158) 1158
male (1008) 1008
female (945) 945
aged (933) 933
middle aged (891) 891
oxonic acid - administration & dosage (862) 862
tegafur - administration & dosage (861) 861
oncology (797) 797
index medicus (765) 765
s-1 (691) 691
antineoplastic combined chemotherapy protocols - therapeutic use (660) 660
adult (642) 642
chemotherapy (606) 606
cancer (538) 538
stomach neoplasms - drug therapy (455) 455
treatment outcome (442) 442
oxonic acid - adverse effects (440) 440
tegafur - adverse effects (438) 438
oxonic acid - therapeutic use (405) 405
tegafur - therapeutic use (404) 404
5-fluorouracil (392) 392
antineoplastic combined chemotherapy protocols - adverse effects (351) 351
medicine & public health (330) 330
cisplatin (304) 304
stomach neoplasms - pathology (299) 299
cisplatin - administration & dosage (288) 288
fluorouracil (286) 286
aged, 80 and over (267) 267
neoplasm staging (254) 254
drug administration schedule (251) 251
stomach cancer (249) 249
gastric cancer (247) 247
trial (245) 245
care and treatment (244) 244
pharmacology & pharmacy (242) 242
survival rate (242) 242
disease-free survival (233) 233
antimetabolites, antineoplastic - therapeutic use (228) 228
cancer research (218) 218
administration, oral (215) 215
antimetabolites, antineoplastic - administration & dosage (205) 205
research (202) 202
carcinoma (185) 185
adenocarcinoma - drug therapy (180) 180
antineoplastic agents (177) 177
antimitotic agents (176) 176
antineoplastic combined chemotherapy protocols - administration & dosage (174) 174
surgery (171) 171
clinical trials (169) 169
therapy (169) 169
surgical oncology (167) 167
antimetabolites, antineoplastic - adverse effects (165) 165
deoxycytidine - analogs & derivatives (160) 160
radiotherapy (154) 154
capecitabine (149) 149
oncology, experimental (149) 149
pyridines - administration & dosage (149) 149
metastasis (148) 148
pharmacology/toxicology (146) 146
retrospective studies (143) 143
oxaliplatin (141) 141
prognosis (141) 141
animals (137) 137
phase-ii (136) 136
chemotherapy, adjuvant (134) 134
follow-up studies (134) 134
dose-response relationship, drug (133) 133
stomach neoplasms - mortality (133) 133
analysis (132) 132
survival (131) 131
adenocarcinoma (127) 127
cancer patients (127) 127
camptothecin - analogs & derivatives (125) 125
docetaxel (124) 124
gemcitabine (123) 123
irinotecan (123) 123
stomach neoplasms - surgery (119) 119
antitumor-activity (118) 118
fluorouracil - administration & dosage (118) 118
adjuvant chemotherapy (117) 117
camptothecin - administration & dosage (112) 112
lung neoplasms - drug therapy (111) 111
toxicity (111) 111
survival analysis (110) 110
maximum tolerated dose (109) 109
kaplan-meier estimate (108) 108
adenocarcinoma - pathology (107) 107
colorectal neoplasms - drug therapy (107) 107
gastroenterology & hepatology (106) 106
combined modality therapy (104) 104
organoplatinum compounds - administration & dosage (104) 104
gastroenterology (103) 103
deoxycytidine - administration & dosage (102) 102
neoplasm metastasis (102) 102
plus cisplatin (101) 101
colorectal cancer (100) 100
pancreatic neoplasms - drug therapy (99) 99
taxoids - administration & dosage (99) 99
combination (98) 98
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Physiology - Renal Physiology, ISSN 1931-857X, 10/2008, Volume 295, Issue 4, pp. 1134 - 1141
Journal Article
Drug metabolism and disposition: the biological fate of chemicals, ISSN 0090-9556, 12/2017, Volume 45, Issue 12, pp. 1354 - 1363
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2006, Volume 17, Issue 6, pp. 968 - 973
Background: A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced... 
Irinotecan | Phase II study | S-1 | Colorectal cancer | ORAL S-1 | MULTICENTER | irinotecan | colorectal cancer | SOLID TUMORS | RATS | ANTITUMOR-ACTIVITY | FLUOROURACIL | TRIAL | CAPECITABINE | 5-FLUOROURACIL | ONCOLOGY | phase II study | CARCINOMA | Adenocarcinoma - pathology | Camptothecin - toxicity | Humans | Middle Aged | Male | Diarrhea - chemically induced | Antimetabolites, Antineoplastic - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - analogs & derivatives | Camptothecin - therapeutic use | Tegafur - toxicity | Tegafur - therapeutic use | Survivors | Anemia - chemically induced | Treatment Outcome | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - toxicity | Antineoplastic Agents, Phytogenic - toxicity | Disease-Free Survival | Oxonic Acid - toxicity | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - toxicity | Tegafur - administration & dosage | Anorexia - chemically induced | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Drug Combinations
Journal Article
Journal Article
Food Chemistry, ISSN 0308-8146, 01/2019, Volume 272, pp. 453 - 461
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 12/2010, Volume 127, Issue 11, pp. 2699 - 2706
The combination therapy of CPT‐11, a prodrug of SN‐38, with S‐1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, shows a high clinical response... 
S‐1 | NK012 | drug delivery system | diarrhea | non‐small cell lung cancer | non-small cell lung cancer | S-1 | IRINOTECAN CPT-11 | THYMIDYLATE SYNTHASE | COMBINATION THERAPY | TUMOR XENOGRAFTS | ONCOLOGY | GASTRIC-CANCER | RANDOMIZED PHASE-III | COLORECTAL-CANCER | GENE-EXPRESSION | GROWTH-FACTOR | THYMIDINE PHOSPHORYLASE | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Camptothecin - chemistry | Antineoplastic Combined Chemotherapy Protocols - chemistry | Camptothecin - toxicity | Humans | Dihydrouracil Dehydrogenase (NADP) - biosynthesis | Oxonic Acid - chemistry | Intestinal Mucosa - drug effects | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Delivery Systems | RNA, Messenger - biosynthesis | Micelles | Thymidylate Synthase - biosynthesis | Camptothecin - administration & dosage | Female | Tegafur - chemistry | Camptothecin - analogs & derivatives | Lung Neoplasms - genetics | Oxonic Acid - pharmacology | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Tegafur - toxicity | RNA, Messenger - genetics | Tegafur - pharmacology | Oxonic Acid - administration & dosage | Thymidylate Synthase - genetics | Antineoplastic Combined Chemotherapy Protocols - toxicity | Drug Synergism | Xenograft Model Antitumor Assays | Oxonic Acid - toxicity | Animals | Mice, Nude | Cell Line, Tumor | Tegafur - administration & dosage | Mice | Mice, Inbred BALB C | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Camptothecin - pharmacology | Dihydrouracil Dehydrogenase (NADP) - genetics | Drug Combinations | Intestinal Mucosa - pathology | Index Medicus
Journal Article
Food & function, ISSN 2042-6496, 10/2016, Volume 7, Issue 10, pp. 4239 - 4246
Journal Article